Conclusions
•
Immunotherapy has arrived to urothelial cancer and solid results have
been achieved in 2L and beyond and in 1L cisplatin ineligible
•
Remarkable responses in patients heavily pre-treated and with scarce
treatment options
•
Treatment is well tolerated and activity appears across all different PD-L1
status
•
Nevertheless patient selection still remains a relevant issue and our efforts
should go in that direction
